Richard E. Pratley
Impact in
- Endocrinology, Diabetes and Metabolism top 0.01%
- Diabetes Treatment and Management
- Diabetes Management and Research
- Endocrine and Autonomic Systems top 0.05%
- Regulation of Appetite and Obesity
Papers in
-
- Diabetes Treatment and Management 191
- Diabetes Management and Research 100
- Diabetes, Cardiovascular Risks, and Lipoproteins 39
- Physiology 76
- Diet and metabolism studies 33
- Adipose Tissue and Metabolism 32
- Co-authors
- Pietro Antonio Tataranni (30 shared papers)Clifton Bogardus (31 shared papers)Christian Weyer (17 shared papers)Eric Ravussin (26 shared papers)C. Weyer (8 shared papers)Tohru Funahashi (2 shared papers)Yūji Matsuzawa (2 shared papers)Sachiyo Tanaka (1 shared paper)
- Journals
- Diabetes Care (69 papers)Diabetes (44 papers)Diabetes Obesity and Metabolism (39 papers)The Journal of Clinical Endocrinology & Metabolism (17 papers)Diabetologia (15 papers)
- Partner nations
- United StatesUnited KingdomDenmark
In The Last Decade
Richard E. Pratley
478 papers receiving 47.3k citations
Richard E. Pratley's Hit Papers
Peers
Comparison fields: 5 of 178
- Endocrinology, Diabetes and Metabolism 19.7k
- Endocrine and Autonomic Systems 4.8k
- Physiology 9.2k
- Epidemiology 7.2k
- Nutrition and Dietetics 3.0k
Countries citing papers authored by Richard E. Pratley
This map shows the geographic impact of Richard E. Pratley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard E. Pratley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard E. Pratley more than expected).
Fields of papers citing papers by Richard E. Pratley
This network shows the impact of papers produced by Richard E. Pratley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard E. Pratley. The network helps show where Richard E. Pratley may publish in the future.
Co-authors
The 25 scholars most cited alongside Richard E. Pratley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 497 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects Hit paper breakdown → | 1995 | 3219 |
| 2 | Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia Hit paper breakdown → | 2001 | 3008 |
| 3 | 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023 Hit paper breakdown → | 2022 | 1664 |
| 4 | The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus Hit paper breakdown → | 1999 | 1565 |
| 5 | Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes Hit paper breakdown → | 2020 | 1166 |
| 6 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Hit paper breakdown → | 2021 | 1134 |
| 7 | Impaired Fasting Glucose and Impaired Glucose Tolerance Hit paper breakdown → | 2007 | 1127 |
| 8 | 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 Hit paper breakdown → | 2023 | 1074 |
| 9 | Diabetes in Older Adults Hit paper breakdown → | 2012 | 943 |
| 10 | Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Hit paper breakdown → | 2020 | 909 |
| 11 | 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023 Hit paper breakdown → | 2022 | 663 |
| 12 | Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance Hit paper breakdown → | 2000 | 644 |
| 13 | Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial Hit paper breakdown → | 2018 | 630 |
| 14 | Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Hit paper breakdown → | 2021 | 622 |
| 15 | 2002 | 618 | |
| 16 | 1999 | 524 | |
| 17 | Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Hit paper breakdown → | 2010 | 510 |
| 18 | 2001 | 509 | |
| 19 | Vitamin D Supplementation and Prevention of Type 2 Diabetes Hit paper breakdown → | 2019 | 499 |
| 20 | 2002 | 491 |
About Richard E. Pratley
Richard E. Pratley is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology, Endocrine and Autonomic Systems, Surgery and Molecular Biology, having authored 497 papers that have together received 49.3k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (191 papers), Diabetes Management and Research (100 papers), Metabolism, Diabetes, and Cancer (59 papers), Pancreatic function and diabetes (43 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (39 papers), Diabetes and associated disorders (34 papers), Diet and metabolism studies (33 papers) and Adipose Tissue and Metabolism (32 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (19.7k citations), Endocrine and Autonomic Systems (4.8k citations), Physiology (9.2k citations), Epidemiology (7.2k citations) and Nutrition and Dietetics (3.0k citations). Richard E. Pratley has collaborated with scholars based in United States, United Kingdom and Denmark. Frequent co-authors include Pietro Antonio Tataranni, Clifton Bogardus, Christian Weyer, Eric Ravussin, C. Weyer, Tohru Funahashi, Yūji Matsuzawa, Sachiyo Tanaka, Kikuko Hotta and David M. Mott. Their work appears in journals such as Diabetes Care, Diabetes, Diabetes Obesity and Metabolism, The Journal of Clinical Endocrinology & Metabolism and Diabetologia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.